BORRBangladesh Open Research Repository
SearchSubmitAboutContact
BORRResearch for a Better Bangladesh.
AboutSubmit PaperContactTermsPolicyGitHub

© 2026 Bangladesh Open Research Repository.

Filters

Sort By

Sort by dateSort by citations
Year Range
to
Clear all filters

All Papers

16+ results
Field: PARP inhibition in cancer therapy

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

Verified

James Perry, Normand Laperrière, Christopher J. O’Callaghan, Alba A. Brandes et al.

Journal: New England Journal of Medicine
Year: 2017
Citations: 1171

BACKGROUND: Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy is added to standard radiotherapy (60 Gy over a period of 6 weeks). In elderly patients, more convenient shorter c...

Health SciencesMedicineGeneticsOpen Access
Read Source

Nicotinamide riboside is uniquely and orally bioavailable in mice and humans

Verified

Samuel A.J. Trammell, Mark S. Schmidt, Benjamin J. Weidemann, Philip Redpath et al.

Journal: Nature CommunicationsYear: 2016Citations: 702

Abstract Nicotinamide riboside (NR) is in wide use as an NAD + precursor vitamin. Here we determine the time and dose-dependent effects of NR on blood NAD + metabolism in humans. We report that human blood NAD + can rise as much as 2.7-fold with a single oral dose of NR in a pilot study of one indiv...

Life SciencesBiochemistry, Genetics and Molecular BiologyPhysiologyOpen Access
Read Source

Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft

Verified

Joana M. Senra, Brian A. Telfer, Kim E. Cherry, Cian M. McCrudden et al.

Journal: Molecular Cancer TherapeuticsYear: 2011Citations: 194

PARP-1 is a critical enzyme in the repair of DNA strand breaks. Inhibition of PARP-1 increases the effectiveness of radiation in killing tumor cells. However, although the mechanism(s) are well understood for these radiosensitizing effects in vitro, the underlying mechanism(s) in vivo are less clear...

Health SciencesMedicineOncologyOpen Access
Read Source

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.

Verified

Paul Hoskins, Elizabeth A. Eisenhauer, Sandra Beare, Manas Pratim Roy et al.

Journal: Journal of Clinical OncologyYear: 1998Citations: 172

PURPOSE: As topotecan is S-phase-specific, its efficacy is likely schedule-dependent. Therefore, a randomized study using a "pick the winner" design was undertaken to compare two schedules in patients with recurrent ovarian cancer. PATIENTS AND METHODS: Patients with recurrent epithelial ovarian can...

Health SciencesMedicineReproductive Medicine
Read Source

Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival

Verified

Asima Mukhopadhyay, Elizabeth Ruth Plummer, Ahmed Elattar, San Soohoo et al.

Journal: Cancer ResearchYear: 2012Citations: 165

Up to 50% of epithelial ovarian cancers (EOC) display defects in the homologous recombination (HR) pathway. We sought to determine the ramifications of the homologous recombination-deficient (HRD) status on the clinicopathologic features, chemotherapy response, and survival outcomes of patients with...

Health SciencesMedicineOncologyOpen Access
Read Source

Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements

Verified

Salima Akter, Md. Ataur Rahman, Mohammad Nazmul Hasan, Hajara Akhter et al.

Journal: CellsYear: 2022Citations: 99

Aggressive and recurrent gynecological cancers are associated with worse prognosis and a lack of effective therapeutic response. Ovarian cancer (OC) patients are often diagnosed in advanced stages, when drug resistance, angiogenesis, relapse, and metastasis impact survival outcomes. Currently, surgi...

Health SciencesMedicineReproductive MedicineOpen Access
Read Source

Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells

Verified

Catherine Wilson, Timothy R. Wilson, Patrick G. Johnston, Daniel B. Longley et al.

Journal: Molecular Cancer TherapeuticsYear: 2008Citations: 98

Chemotherapy-induced interleukin-8 (IL-8) signaling reduces the sensitivity of prostate cancer cells to undergo apoptosis. In this study, we investigated how endogenous and drug-induced IL-8 signaling altered the extrinsic apoptosis pathway by determining the sensitivity of LNCaP and PC3 cells to ad...

Life SciencesBiochemistry, Genetics and Molecular BiologyMolecular Biology
Read Source

Pharmacologic characterization of fluzoparib, a novel poly(<scp>ADP</scp>‐ribose) polymerase inhibitor undergoing clinical trials

Verified

Lei Wang, Changyong Yang, Chengying Xie, Jiahua Jiang et al.

Journal: Cancer ScienceYear: 2019Citations: 92

Poly( ADP ‐ribose) polymerase ( PARP ) enzymes play an important role in repairing DNA damage and maintaining genomic stability. Olaparib, the first‐in‐class PARP inhibitor, has shown remarkable clinical benefits in the treatment of BRCA ‐mutated ovarian or breast cancer. However, the undesirable he...

Health SciencesMedicineOncologyOpen Access
Read Source

Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer

Verified

Md. Mominur Rahman, Tapan Behl, Md. Rezaul Islam, Md Noor A Alam et al.

Journal: MoleculesYear: 2022Citations: 53

Immunotherapy, which stimulates the body's immune system, has received a considerable amount of press in recent years because of its powerful benefits. Cancer immunotherapy has shown long-term results in patients with advanced disease that are not seen with traditional chemotherapy. Immune checkpoin...

Health SciencesMedicineOncologyOpen Access
Read Source

The “Delta Plus” COVID-19 variant has evolved to become the next potential variant of concern: mutation history and measures of prevention

Verified

Fahad Imtiaz Rahman, Sadia Afruz Ether, Md. Rabiul Islam

Journal: Journal of Basic and Clinical Physiology and PharmacologyYear: 2021Citations: 49

Article The “Delta Plus” COVID-19 variant has evolved to become the next potential variant of concern: mutation history and measures of prevention was published on January 1, 2022 in the journal Journal of Basic and Clinical Physiology and Pharmacology (volume 33, issue 1).

Health SciencesMedicineInfectious Diseases
Read Source

The Deltacron conundrum: Its origin and potential health risks

Verified

Saria Farheen, Yusha Araf, Yan‐Dong Tang, Chunfu Zheng

Journal: Journal of Medical VirologyYear: 2022Citations: 40

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), since its outbreak in December 2019, has been capable of continuing the pandemic by mutating itself into different variants. Mass vaccinations, antibiotic treatment therapy, herd immunity, and preventive measures have reduced the disease'...

Health SciencesMedicineInfectious Diseases
Read Source

The Significance of <i>Tinospora crispa</i> in Treatment of Diabetes Mellitus

Verified

Alex Thomas, Elizabeth Rajesh, Dharmendra Kumar

Journal: Phytotherapy ResearchYear: 2016Citations: 40

Tinospora crispa is a medicinal plant belonging to the botanical family Menispermiaceae. The plant is widely distributed in Southeast Asia and the northeastern region of India. A related species Tinospora cordifolia is used in Ayurveda for treating a large spectrum of diseases. Traditional healers o...

Health SciencesMedicineComplementary and alternative medicine
Read Source

Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer

Verified

Eileen E. Parkes, Richard D. Kennedy

Journal: The OncologistYear: 2016Citations: 35

UNLABELLED: : High-grade serous ovarian cancer is characterized by genomic instability, with one half of all tumors displaying defects in the important DNA repair pathway of homologous recombination. Given the action of poly(ADP-ribose) polymerase (PARP) inhibitors in targeting tumors with deficienc...

Health SciencesMedicineOncologyOpen Access
Read Source

Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population

Verified

Salma Parvin, Md. Siddiqul Islam, Mir Md. Abdullah Al-Mamun, Mohammad Safiqul Islam et al.

Journal: Breast CancerYear: 2016Citations: 27

Purpose Breast cancer is considered as the most frequent female malignancy. Altered gene expressions due to genetic polymorphisms in the BRCA1, BRCA2, RAD51, and HER2 contribute toward the development of breast cancer, and yet, no such type of study has been conducted in the Bangladeshi population. ...

Life SciencesBiochemistry, Genetics and Molecular BiologyGenetics
Read Source

Unravelling the potential neuroprotective facets of erythropoietin for the treatment of Alzheimer’s disease

Verified

Dapinder Kaur, Tapan Behl, Aayush Sehgal, Sukhbir Singh et al.

Journal: Metabolic Brain DiseaseYear: 2021Citations: 26

During the last three decades, recombinant DNA technology has produced a wide range of hematopoietic and neurotrophic growth factors, including erythropoietin (EPO), which has emerged as a promising protein drug in the treatment of several diseases. Cumulative studies have recently indicated the neu...

Health SciencesMedicineHematology
Read Source
PreviousPage 1 of 2+Next